Expected Delivery: 3-4 Days
Business Hours: Monday - Friday: 9 AM - 6 PM EST
David Fuller
Last Updated On: October 1, 2024
In 1997, the Food and Drug Administration (FDA) approved viscosupplementation as a conservative treatment for osteoarthritis (OA), significantly advancing in managing this chronic condition. Since then, viscosupplements like hyaluronic acid injections have become popular for alleviating joint pain and improving mobility in OA patients.
Monovisc is a single-injection treatment designed to provide long-lasting relief from knee OA pain by restoring the natural lubrication and cushioning of the joint. Understanding the safety and efficacy of Monovisc is essential for those considering it as a treatment option.
In this article, we will explore the FDA approval process for Monovisc, examine its safety profile, and discuss what patients can expect from this treatment.
About: Operating since 2016, Med Supply Solutions is known for being one of the industry’s top and trusted suppliers of cosmetic and viscosupplementation products. If you’re looking to buy Monovisc online, contact our sales department for more information.
SODIUM HYALURONATE
$349.00
Tier pricing
Save 2.87%
3 or more
$339.00 each
Save 4.3%
11 or more
$334.00 each
Save 5.73%
21 or more
$329.00 each
Monovisc is a single-injection treatment designed to alleviate knee pain caused by osteoarthritis. It is formulated with hyaluronic acid derived from non-animal sources, making it suitable for a wide range of patients, particularly those who haven’t found relief with other arthritis treatments.
It is important to note that patients should avoid Monovisc if they are allergic to hyaluronate preparations. Thanks to the FDA’s rigorous approval process, treatments like Monovisc offer a safe and effective option for knee pain management.
The convenience of a single injection and its long-lasting effects make Monovisc a preferred choice, especially when compared to alternatives like Monovisc vs Durolane.
Monovisc received FDA approval based on a pivotal phase III clinical trial. This randomized, controlled, double-blind, multicenter study involved 369 patients with osteoarthritis (OA) of the knee across 31 centers in the US and Canada. The study aimed to evaluate the safety and effectiveness of Monovisc for treating joint pain.
Another significant study was conducted at 31 sites across the US between January 2008 and December 2009. This trial examined the safety and effectiveness of Monovisc as a single intra-articular hyaluronic acid (HA) injection for treating idiopathic, symptomatic knee OA.
Anika Therapeutics’ white paper reviews data from published pivotal clinical studies and post-marketing safety databases. It compares Monovisc to other HA treatments like DUROLANE®, Gel-One®, and Synvisc-One®. The analysis suggests that Monovisc provides early and durable pain relief in a single high-dose injection, making it a convenient and effective option for patients.
These studies highlight Monovisc’s potential as a safe and effective treatment for knee osteoarthritis, offering durable pain relief with a single injection.
Monovisc offers new options for treating knee pain caused by osteoarthritis, offering significant benefits for patients and healthcare providers. However, weighing the benefits and considerations before selecting this treatment is crucial.
Monovisc offers hope for those with knee osteoarthritis, particularly those who have tried other methods without success. It provides an effective solution that balances convenience with long-term benefits.
Before administering Monovisc, healthcare providers must evaluate patients for potential allergies to hyaluronate products to ensure the treatment is safe. Providers must also follow the recommended dosage and monitor patients closely for any side effects following the injection.
Patients should openly discuss their medical history and any concerns with their healthcare provider to ensure that Monovisc is the right treatment for them. With its FDA approval and well-established safety profile, Monovisc can effectively manage knee osteoarthritis, but individual considerations are crucial for achieving the best outcomes.
Monovisc has received FDA approval, signifying that it has undergone rigorous testing to demonstrate its safety and efficacy for treating knee pain associated with arthritis. Before administering Monovisc, healthcare providers assess whether other treatments have been insufficient. This approval also offers patients a viable option free from animal-derived components. Therefore, Monovisc is a safe choice for those requiring effective knee pain management.
Monovisc is a single-injection treatment for knee osteoarthritis that uses hyaluronic acid derived from non-animal sources. It works by restoring lubrication and cushioning in the joint, reducing pain, and improving joint function.
Monovisc typically provides relief for up to six months after a single injection, minimizing the need for multiple treatment sessions.
Common side effects include mild pain, swelling, or redness at the injection site. These symptoms typically resolve on their own within a few days. If symptoms persist, consult your healthcare provider for further guidance.
Patients who are allergic to hyaluronate or have had adverse reactions to similar products should avoid Monovisc.
Viscosupplementation in the Therapy for Osteoarthritic Knee. Appl Sci. 2021;11(24):11621. doi:10.3390/app112411621.
Monovisc (sodium hyaluronate) FDA Approval History. Drugs.com. https://www.drugs.com/history/monovisc.html
Products
Cart
Log In
Newsletter
Subscribe for exclusive offers and updates on new arrivals
Share feedback at:
Working Hours
Monday to Friday: 9 AM to 6 PM EST
The Most Popular Brands
Med Supply Solutions
Support
Copyright 2024. Med Supply Solutions